- Merrimack Pharmaceuticals (NASDAQ:MACK) said it has received a $225 million payment which was due from Ipsen as a result of its receipt of approval from the U.S. Food and Drug Administration to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
- Merrimack’s Board of Directors has evaluated the likelihood of receiving additional milestone payments under the Ipsen Agreement and from the 2019 Agreement with Elevation Oncology.
- The company said it has announced a special meeting of stockholders on May 10, 2024 to approve a Plan of Dissolution which includes plans for a liquidating dividend payable to stockholders.
- "We currently anticipate the initial liquidating dividend to be in the range of between approximately $14.68 and $15.30 per share," it said.
- Source: Press Release
Merrimack receives $225M milestone payment from Ipsen
Recommended For You
About MACK Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| MACK | - | - |
| Merrimack Pharmaceuticals, Inc. | ||